fdaheadlines.com
Cymabay Therapeutics Inc. (NASDAQ:CBAY) Provide Corporate Updates Indicating Initiation Of ENHANCE Study Of Seladelpar l In Q42018 - FDA Headlines
CymaBay Therapeutics Inc. (NASDAQ:CBAY) gained 5% in the last trading session to close at $13.22 after the company announced its Q4 and FY2018 results as well as providing a corporate update. Milestones and financial highlights The company had a busy year, and in the Q42018 it achieved a major milestone by initiating the ENHANCE phase …